<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Clearmind Medicine Inc. Common Shares — News on 6ix</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares</link>
<description>Latest news and press releases for Clearmind Medicine Inc. Common Shares on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 11:41:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/clearmind-medicine-inc-common-shares" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835571e78dffbe2df0ea0b1.webp</url>
<title>Clearmind Medicine Inc. Common Shares</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares</link>
</image>
<item>
<title>Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-evaluation-of-its-psychedelic-based-treatment-meai-for-potential-fda-breakthrough-therapy-designation</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-evaluation-of-its-psychedelic-based-treatment-meai-for-potential-fda-breakthrough-therapy-designation</guid>
<pubDate>Mon, 27 Apr 2026 11:41:00 GMT</pubDate>
<description>Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for eligibility for Breakthrough Therapy Designation Vancouver, Canada, April 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it i</description>
</item>
<item>
<title>Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-welcomes-president-trumps-executive-order-as-a-historic-catalyst-for-psychedelic-innovation-and-veteran-mental-health-care</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-welcomes-president-trumps-executive-order-as-a-historic-catalyst-for-psychedelic-innovation-and-veteran-mental-health-care</guid>
<pubDate>Mon, 20 Apr 2026 20:03:00 GMT</pubDate>
<description>Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage psychedelic biotech company focused on the discovery and development of novel, non-hallucinogenic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today commended President Donald J. Trump’s Executive Order signed on April 18, 2026, titled Accelerating Medical Treatments for Serious Mental Illness, which directs the U.S. F</description>
</item>
<item>
<title>Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-positive-data-safety-monitoring-board-recommendation-in-ongoing-cmnd-100-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-positive-data-safety-monitoring-board-recommendation-in-ongoing-cmnd-100-clinical-trial</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Vancouver, Canada, April 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company</description>
</item>
<item>
<title>Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicines-cmnd-100-meets-primary-endpoint-in-fda-approved-phase-iiia-clinical-trial-for-alcohol-use-disorder</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicines-cmnd-100-meets-primary-endpoint-in-fda-approved-phase-iiia-clinical-trial-for-alcohol-use-disorder</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Vancouver, Canada, April 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company</description>
</item>
<item>
<title>Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-successful-completion-of-treatment-and-follow-up-for-18-participants-in-its-ongoing-phase-iiia-clinical-trial-of-cmnd-100-for-alcohol-use-disorder</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-successful-completion-of-treatment-and-follow-up-for-18-participants-in-its-ongoing-phase-iiia-clinical-trial-of-cmnd-100-for-alcohol-use-disorder</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Company completed treatment in four additional participate at its Israel clinical site Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind</description>
</item>
<item>
<title>Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-files-patent-application-in-india-for-next-gen-psychedelic-compounds-to-treat-mental-health-disorders</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-files-patent-application-in-india-for-next-gen-psychedelic-compounds-to-treat-mental-health-disorders</guid>
<pubDate>Fri, 27 Mar 2026 11:32:00 GMT</pubDate>
<description>Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application in India covering innovative next-generation psychedelic-based compounds for the treatment of mental health disorders a</description>
</item>
<item>
<title>Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-reports-successful-ongoing-treatment-of-participants-at-us-sites-in-its-fda-approved-cmnd-100-phase-iiia-clinical-trial-for-alcohol-use-disorder</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-reports-successful-ongoing-treatment-of-participants-at-us-sites-in-its-fda-approved-cmnd-100-phase-iiia-clinical-trial-for-alcohol-use-disorder</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company</description>
</item>
<item>
<title>Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-publication-of-six-innovative-patents-in-hong-kong-for-next-generation-psychedelic-based-combination-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-publication-of-six-innovative-patents-in-hong-kong-for-next-generation-psychedelic-based-combination-therapies</guid>
<pubDate>Tue, 17 Mar 2026 13:15:00 GMT</pubDate>
<description>Vancouver, Canada, March 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of six patents by the Intellectual Property Department in Hong Kong. These patents cover proprietary combination therapies integrating Pal</description>
</item>
<item>
<title>NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/neurothera-labs-clearmind-medicine-collaboration-leads-to-patent-application-for-depression-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/neurothera-labs-clearmind-medicine-collaboration-leads-to-patent-application-for-depression-therapy</guid>
<pubDate>Mon, 16 Mar 2026 11:30:00 GMT</pubDate>
<description>VANCOUVER, BC - March 16, 2026 (NEWMEDIAWIRE) - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd., today announces that pursuant to its ongoing collabo...</description>
</item>
<item>
<title>Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-hong-kong-patent-filing-for-depression-therapy-111</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-hong-kong-patent-filing-for-depression-therapy-111</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to</description>
</item>
<item>
<title>SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/scisparc-neurothera-labs-announces-publication-of-international-patent-in-collaboration-with-clearmind-medicine-for-novel-therapy-targeting-weight-loss-and-fatty-liver-disease-2</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/scisparc-neurothera-labs-announces-publication-of-international-patent-in-collaboration-with-clearmind-medicine-for-novel-therapy-targeting-weight-loss-and-fatty-liver-disease-2</guid>
<pubDate>Thu, 12 Mar 2026 11:55:00 GMT</pubDate>
<description>TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under th</description>
</item>
<item>
<title>Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-advances-recruitment-for-cmnd-100-trials-third-cohort-at-yale-johns-hopkins-and-tel-aviv-sites-following-recent-positive-topline-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-advances-recruitment-for-cmnd-100-trials-third-cohort-at-yale-johns-hopkins-and-tel-aviv-sites-following-recent-positive-topline-results-1</guid>
<pubDate>Wed, 11 Mar 2026 13:07:00 GMT</pubDate>
<description>Vancouver, Canada, March 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s</description>
</item>
<item>
<title>NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/neurothera-labs-announces-publication-of-international-patent-in-collaboration-with-clearmind-medicine-for-novel-therapy-targeting-weight-loss-and-fatty-liver-disease</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/neurothera-labs-announces-publication-of-international-patent-in-collaboration-with-clearmind-medicine-for-novel-therapy-targeting-weight-loss-and-fatty-liver-disease</guid>
<pubDate>Wed, 11 Mar 2026 11:30:00 GMT</pubDate>
<description>VANCOUVER, BRITISH COLUMBIA - March 11, 2026 (NEWMEDIAWIRE) - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd., has advanced its collaboration with Cl...</description>
</item>
<item>
<title>Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-publication-of-international-patent-for-novel-therapy-targeting-weight-loss-and-fatty-liver-disease-16</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-publication-of-international-patent-for-novel-therapy-targeting-weight-loss-and-fatty-liver-disease-16</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver</description>
</item>
<item>
<title>Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-moving-forward-to-the-next-stage-of-its-clinical-trial-following-data-and-safety-monitoring-board-approval</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-moving-forward-to-the-next-stage-of-its-clinical-trial-following-data-and-safety-monitoring-board-approval</guid>
<pubDate>Wed, 04 Mar 2026 12:30:00 GMT</pubDate>
<description>The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial Vancouver, Canada, March 04, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that</description>
</item>
<item>
<title>Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/moonage-media-review-clearminds-meai-and-glp-1-are-these-the-next-generation-treatment-for-weight-loss</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/moonage-media-review-clearminds-meai-and-glp-1-are-these-the-next-generation-treatment-for-weight-loss</guid>
<pubDate>Thu, 19 Feb 2026 18:05:00 GMT</pubDate>
<description>As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments, Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, recently reported additional progress related to its proprietary, non-hallucinogenic neuroplastogen, MEAI.</description>
</item>
<item>
<title>Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-additional-topline-131700754</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-announces-additional-topline-131700754</guid>
<pubDate>Mon, 09 Feb 2026 13:17:00 GMT</pubDate>
<description>Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinog</description>
</item>
<item>
<title>Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-enters-development-agreement-125500892</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-enters-development-agreement-125500892</guid>
<pubDate>Fri, 06 Feb 2026 12:55:00 GMT</pubDate>
<description>Collaboration aims to enhance bioavailability and support clinical advancement of Clearmind’s lead MEAI candidate for addiction-related and other CNS disorders Vancouver, Canada, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered in</description>
</item>
<item>
<title>Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/excellent-achievements-clearmind-proprietary-meai-130000232</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/excellent-achievements-clearmind-proprietary-meai-130000232</guid>
<pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
<description>This is the first time MEAI, Clearmind’s next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation Vancouver, Canada, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today welcomes the inclusion of its proprietary compound, MEAI</description>
</item>
<item>
<title>Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025</title>
<link>https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-inc-files-annual-212000819</link>
<guid isPermaLink="true">https://6ix.com/company/clearmind-medicine-inc-common-shares/news/clearmind-medicine-inc-files-annual-212000819</guid>
<pubDate>Tue, 20 Jan 2026 21:20:00 GMT</pubDate>
<description>Vancouver, Canada, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended October 31, 2025, with the U.S. Securities and Exchange Commission (the 'SEC'). The report is available on</description>
</item>
</channel>
</rss>